Medscape Medical NewsAll articles

Rapid

iSchema View Inc. • Radiology • 02/08/2022

510(k)IEC 62304 Class B
FDA Summary PDF

Device Purpose

The Rapid software by iSchemaView is a comprehensive medical image processing system utilizing CT and MRI data to enhance diagnostic capabilities, particularly for acute stroke assessment and patient selection for thrombectomy. It integrates advanced analytical modules, including AI/ML for NCCT motion artifact detection and specific tools for perfusion, diffusion, and angiographic analysis, aiming to provide clinicians with timely and quantitative insights for critical treatment decisions.

Summary

Rapid, by iSchemaView Inc., is an advanced image processing software package designed for trained medical professionals to view, process, and analyze medical images from CT and MRI scanners. It operates on standard off-the-shelf computers or virtual platforms, acquiring DICOM-compliant image data to assist physicians in diagnosis. The software suite includes modules for CT Perfusion (CTP), CT Angiography (CTA), and MRI, featuring a Diffusion Weighted MRI (DWI) Module for visualizing local water diffusion properties and a Dynamic Analysis Module for assessing changes in contrast over time, thereby calculating parameters related to tissue flow and blood volume. A primary application is its utility in aiding physicians in the selection of acute stroke patients with known intracranial occlusions for endovascular thrombectomy, based on specific imaging criteria in conjunction with clinical assessment; contraindications include inadequate contrast bolus, excessive patient motion, or presence of hemorrhage. The Rapid system's CT analysis capabilities include generating Non-Contrast CT (NCCT) maps that delineate areas of hypodense and hyperdense tissue. A notable technological feature is its NCCT Motion Artifact AI/ML Module, which utilizes artificial intelligence and machine learning—trained on a dataset of 23,066 axial image slices and validated on an independent set of 619 cases from multiple scanner vendors—to detect motion artifacts with reported optimal performance (AUC=0.95, Sensitivity=0.95, Specificity=0.96 in training; independent validation AUC=0.96, Sensitivity=0.91, Specificity=0.86). The software is designed for streamlined workflow integration with minimal user interaction post-installation and features a server-based architecture (Rapid Server as a processing engine, connecting to a hospital LAN or via a virtualized appliance) for image processing and secure data management, including encrypted hard disks and secure network connections (VPN, SSH). Performance validation testing has confirmed its accuracy in representing key processing parameters and its compliance with DICOM standards.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

Image Processing SoftwareDICOMCT Perfusion (CTP)MRI Diffusion (DWI)Acute StrokeThrombectomy SelectionNCCT AnalysisAI/MLMotion Artifact DetectionMedical Image Analysis

Device Metadata

Submission Number
K213165
Company
iSchema View Inc.
Panel
Radiology
Product Code
N/A
Data Type
Images
Clinical Function
Assessment
AI Function
Analysis
AI Subclass
quantification/feature localization

Relevant Clinical Questions

  • Q1. How does the performance of the NCCT Motion Artifact AI/ML Module vary across different CT scanner manufacturers and imaging protocols not included in the initial training and validation datasets?; What is the typical processing time for a complete stroke protocol dataset (e.g., NCCT, CTA, CTP) using Rapid, and how does this impact time-critical emergency stroke workflows?; Are there specific thresholds or quantitative outputs from the Dynamic Analysis Module (e.g., tissue flow, blood volume) that have been correlated with patient outcomes post-thrombectomy?; How does the software handle co-registration of images from different modalities (e.g., CT and MRI) or images acquired at different time points, and what is the typical accuracy of this co-registration?; What are the specific imaging criteria that Rapid CT-Perfusion and Rapid MR-Perfusion utilize to aid in the selection of acute stroke patients for thrombectomy, and how sensitive are these criteria to variations in contrast agent administration or bolus quality?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score35/100
SBOM Evidence✓ Detected in Summary
Cyber Risk Assessment⚠ Not mentioned in summary
Postmarket Plan⚠ Not mentioned in summary
§524B ApplicableNo

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials(software package)
✓ Detected
ML-BOMMachine Learning Bill of Materials(machine learning, dataset)
✓ Detected
SaaSBOMSoftware-as-a-Service Bill of Materials(server, network, platform)
✓ Detected
HBOMHardware Bill of Materials
- Not detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials
- Not detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of SBOM, ML-BOM, SaaSBOM detected in AI-generated device summary.

• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.

• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.

• Not detected in AI-generated device summary: HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
Rapid - iSchema View Inc. | ESL FDA AI Device Intelligence